{"id":"W3093926168","doi":"10.1136/bmjopen-2020-038861","title":"Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study","year":2020,"lang":"en","type":"article","venue":"BMJ Open","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Canadian Institutes of Health Research; EMD Serono; Ministero della Salute; Multiple Sclerosis Society of Canada; Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica; Genentech; Multiple Sclerosis Society; Serono Symposia International Foundation; International Progressive MS Alliance; Acorda Therapeutics; Eli Lilly and Company; Fondazione Italiana Sclerosi Multipla; Biogen; GlaxoSmithKline; Teva Pharmaceutical Industries","keywords":"Fingolimod; Medicine; Natalizumab; Multiple sclerosis; Internal medicine; Clinical endpoint; Lesion; Population; Randomized controlled trial; Prospective cohort study; Pediatrics; Physical therapy; Surgery; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004160813,0.00120812,0.003293396,0.0003980643,0.0003802027,0.001004811,0.0006885281,0.001275861,0.004118101],"category_scores_gemma":[0.003842905,0.0008944396,0.002300769,0.0004874132,0.0008622289,0.001078213,0.0005209456,0.00156641,0.0007925304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008621616,"about_ca_system_score_gemma":0.001711545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001200522,"about_ca_topic_score_gemma":0.003546749,"domain_scores_codex":[0.9978917,0.001454581,0.0001621506,0.0001594547,0.0001650732,0.0001670126],"domain_scores_gemma":[0.9977123,0.0007724533,0.000804077,0.0002138595,0.0001297638,0.0003675584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9780443,0.004381808,0.002739299,0.0003892731,0.001413095,0.00003189694,0.0001011002,0.0001760983,0.002309533,0.00004202962,0.0002778676,0.01009369],"study_design_scores_gemma":[0.7680527,0.2074138,0.01837152,0.00006680744,0.003527009,0.00008486839,0.00009098974,0.0003350225,0.0009422936,0.00009482563,0.000988267,0.00003185778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939365,0.003354871,0.0002290056,0.0002801181,0.00009459058,0.0006755902,0.0006545832,0.00003165612,0.0007431184],"genre_scores_gemma":[0.9937392,0.002022592,0.0006631621,0.0004062779,0.000256366,0.001187786,0.0006232137,0.00001737889,0.001083966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004160813,"threshold_uncertainty_score":0.02200472,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.210578022137334,"score_gpt":0.4088607370215846,"score_spread":0.1982827148842506,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}